Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers
Conditions: Acute Myeloid Leukemia; Relapsed Cancer; Refractory Cancer; IDH2 Gene Mutation Interventions: Drug: Enasidenib; Drug: Venetoclax Sponsors: University Health Network, Toronto; Celgene; AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials